ADS-5102 extended-release capsules are an oral formulation of amantadine administered once daily at bedtime in patients with Parkinson’s disease (PD) to treat dyskinesia associated with the use of levodopa.

Pooled results from two randomized, double-blind, placebo-controlled, phase III trials confirm that treatment with ADS-5102 is associated with a significant improvement over placebo for dyskinesia in as early as two weeks and maintained over 12 weeks (relative treatment difference between groups = 27.3%; p < 0.0001). A significant improvement in the total daily duration of OFF time was also achieved.

These results provide further evidence supporting ADS-5102 as an adjunct to levodopa for both dyskinesia and OFF time in PD patients with dyskinesia.